Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: TG6002

Transgene Receives MHRA Approval for a Clinical Trial of TG6002, a Next-generation Oncolytic Virus, Administered by Intrahepatic Artery Infusion in Patients with Colorectal Cancer with Liver Metastases

20190718 – TRANSGENE PR MHRA TG6002

Published 18 July 2019
Categorized as 2019, Press release, TG6002

Peer-reviewed publications confirm the potential of Transgene’s TG4001 and TG6002

20190605 Transgene publi TG4001 TG6002 EN

Published 5 June 2019
Categorized as 2019, Press release, TG4001, TG6002

The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism

Johann Foloppe, et al. Molecular Therapy Oncolytics, March 2019 – Download the article Publication

Published 27 March 2019
Categorized as -others, 2019, Publication, TG6002

First Patient Dosed in a Phase 1/2 Trial of Transgene’s Oncolytic Virus TG6002 Administered Intravenously in Patients with Advanced Gastrointestinal Tumors

20181017 PR TG6002 US

Published 17 October 2018
Categorized as 2018, Press release, TG6002

Transgene completes the sale of the Greater China rights of TG6002 and TG1050 to Tasly Biopharmaceuticals for $48 million in newly-issued shares

180820 – TG Tasly Closing EN

Published 20 August 2018
Categorized as 2018, Press release, TG1050, TG6002

Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of TG6002 and TG1050 in Greater China

180710 – TG Tasly agreement PR

Published 10 July 2018
Categorized as 2018, Press release, TG1050, TG6002

TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma

Johann Foloppe, et al. International Oncolytic Virus Conference, April 2018 Download the poster here Poster Presentation

Published 17 April 2018
Categorized as -others, 2018, Publication, TG6002

First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma

20171026-PR-TG6002

Published 26 October 2017
Categorized as 2017, Press release, TG6002

Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy

Laetitia Fend, et al. Cancer Research, July 2017, DOI: 10.1158/0008-5472.CAN-16-2165 – Download the article Publication

Published 24 July 2017
Categorized as -others, 2017, Publication, TG6002

TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma

Ahmed Idbaih, et al. ASCO 2017, June 2017 – Download the abstract Abstract

Published 5 June 2017
Categorized as -others, 2017, Publication, TG6002

Posts pagination

Newer posts Page 1 … Page 3 Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu